Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-08-05

Study Completion Date

2024-12-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression (treatment authorisations granted in advance by the Federal Officie of Public Health for compassionate use of the substance).

There will be no interference with the usual clinical routine in our Service. The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment.

Participants will be asked to give 4 saliva samples the day of their LSD treatment .In addition they will fill-in self-report questionnaires which are part of the clinical routine

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study

NCT01878942

Healthy

COMPLETED EARLY_PHASE1

Oxytocin and the Processing of Social Stress-Associated Chemosignals

NCT03265899

Healthy Volunteers

COMPLETED PHASE1

Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects

NCT04516902

Healthy

COMPLETED PHASE1

LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects

NCT04865653

Healthy

COMPLETED PHASE1

Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self

NCT03736980

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression, Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lysergic Acid Diethylamide (LSD)

one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ongoing psychotherapy with a certified psychotherapist, anxiety disorder or depression resistant to usual treatments, agreement to stop necessary medication

Exclusion Criteria

* Exclusion: psychotic or bipolar disorder, high suicidal risk, severe cardiovascular disease, severe liver disease, neurological disease of the central nervous system, pregnancy and breastfeeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No